TY  - JOUR
AU  - Maier, Franziska
AU  - Spottke, Annika
AU  - Bach, Jan-Philipp
AU  - Bartels, Claudia
AU  - Bürger, Katharina
AU  - Dodel, Richard
AU  - Fellgiebel, Andreas
AU  - Fliessbach, Klaus
AU  - Frölich, Lutz
AU  - Hausner, Lucrezia
AU  - Hellmich, Martin
AU  - Klöppel, Stefan
AU  - Klostermann, Arne
AU  - Kornhuber, Johannes
AU  - Laske, Christoph
AU  - Peters, Oliver
AU  - Priller, Josef
AU  - Richter-Schmidinger, Tanja
AU  - Schneider, Anja
AU  - Shah-Hosseini, Kija
AU  - Teipel, Stefan
AU  - von Arnim, Christine A. F.
AU  - Wiltfang, Jens
AU  - Jessen, Frank
TI  - Bupropion for the Treatment of Apathy in Alzheimer Disease
JO  - JAMA network open
VL  - 3
IS  - 5
SN  - 2574-3805
CY  - Chicago, Ill.
PB  - American Medical Association
M1  - DZNE-2020-01242
SP  - e206027
PY  - 2020
AB  - Importance  Apathy is a frequent neuropsychiatric symptom in dementia of Alzheimer type and negatively affects the disease course and patients’ and caregivers’ quality of life. Effective treatment options are needed.Objective  To examine the efficacy and safety of the dopamine and noradrenaline reuptake inhibitor bupropion in the treatment of apathy in patients with dementia of Alzheimer type.Design, Setting, and Participants  This 12-week, multicenter, double-blind, placebo-controlled, randomized clinical trial was conducted in a psychiatric and neurological outpatient setting between July 2010 and July 2014 in Germany. Patients with mild-to-moderate dementia of Alzheimer type and clinically relevant apathy were included. Patients with additional clinically relevant depressed mood were excluded. Data analyses were performed between August 2018 and August 2019.Interventions  Patients received either bupropion or placebo (150 mg for 4 weeks plus 300 mg for 8 weeks). In case of intolerability of 300 mg, patients continued to receive 150 mg throughout the study.Main Outcomes and Measures  Change on the Apathy Evaluation Scale–Clinician Version (AES-C) (score range, 18-72 points) between baseline and week 12 was the primary outcome parameter. Secondary outcome parameters included measures of neuropsychiatric symptoms, cognition, activities of daily living, and quality of life. Outcome measures were assessed at baseline and at 4, 8, and 12 weeks.Results  A total of 108 patients (mean [SD] age, 74.8 [5.9] years; 67 men [62
LB  - PUB:(DE-HGF)16
C6  - pmid:32463470
DO  - DOI:10.1001/jamanetworkopen.2020.6027
UR  - https://pub.dzne.de/record/151663
ER  -